Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Polivy Market Size Forecast: How Large Could The Market Become By 2030?
Several factors fueled growth during the historic period, including a rising prevalence of diffuse large B-cell lymphoma, progress in developing monoclonal antibodies, the proliferation of oncology treatment centers, greater uptake of targeted cancer therapies, and enhancements in diagnostic techniques.
The expansion during the forecast period is driven by the rising need for customized oncology medications, heightened funding for ADC research initiatives, the broadening application of first-line combination treatments, a greater emphasis on addressing treatment-resistant lymphomas, and a surge in regulatory clearances for targeted biologics. Key developments shaping this period involve the escalating utilization of antibody-drug conjugates, their increasing incorporation into targeted lymphoma therapies, more frequent pairing with combination chemotherapy protocols, the advancement of precision oncology approaches, and a heightened concentration on drugs targeting CD79b.
Download A Free Sample Report For Comprehensive Market Insights:
Polivy Market Growth Momentum: Which Factors Are Influencing Demand?
The growing prevalence of diffuse large B-cell lymphoma is anticipated to drive expansion in the polivy market in the coming years. Diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma (NHL), is characterized as a highly aggressive blood cancer originating from B-lymphocytes—white blood cells crucial for the immune system’s role in producing antibodies to fight infections. This rising incidence is linked to multiple factors, such as an aging population, increased immunosuppression from conditions like HIV/AIDS and organ transplants, and environmental exposures that contribute to the disease’s development. Polivy is administered alongside chemotherapy for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in individuals who have undergone prior therapies. For example, in July 2024, a report from the Royal College of Pathologists, a UK-based professional membership organization, indicated that approximately 5,500 people are diagnosed annually in the UK with diffuse large B-cell lymphoma (DLBCL), a highly aggressive form of non-Hodgkin lymphoma. Around 30% of these patients will face refractory disease or relapse soon after their initial treatment. Consequently, the increasing incidence of diffuse large B-cell lymphoma is fueling growth in the polivy market.
Polivy Market Driver: Rising Number Of Oncology Procedures Boosts Demand For Polivy
An uptick in oncology procedures is expected to accelerate growth in the polivy market moving forward. Oncology procedures encompass medical tests, treatments, and interventions designed to diagnose, manage, and treat various cancer types. The increase in these procedures stems from a greater emphasis by healthcare providers and patients on early cancer detection and access to effective targeted therapies. Polivy is instrumental in this trend by delivering targeted therapy that enhances outcomes and broadens treatment options for cancer patients. For instance, in February 2024, the World Health Organization, a US-based United Nations agency, projected that over 35 million new cancer cases will be diagnosed in 2050, representing a 77% rise from the estimated 20 million cases in 2022. Thus, the growing number of oncology procedures is propelling the polivy market forward.
Polivy Market Segments: Where Are The Largest Growth Opportunities?
The polivy market covered in this report is segmented –
1) By Indication: Previously Untreated Diffuse Large B-Cell Lymphoma, Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
2) By Dosage Form: Injectable Solution
3) By Distribution Channel: Direct Sales, Pharmaceutical Wholesalers, Online Pharmacies
Polivy Market Trends Reshaping Industry Growth
Major players in the polivy market are prioritizing the creation of innovative treatment regimens—particularly first-line antibody-drug conjugate (ADC) combinations—designed to more effectively target aggressive B-cell lymphomas while boosting patient outcomes. In such a first-line ADC combination, a monoclonal antibody that precisely attaches to tumor-specific proteins is paired with a cytotoxic payload, enabling highly targeted therapy, a stark contrast to traditional chemotherapy that damages both cancerous and healthy tissues. As an example, in April 2023, Genentech, a biotechnology firm based in the United States, secured FDA approval for Polivy (polatuzumab vedotin-piiq) when used alongside R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) for adults with previously untreated diffuse large B-cell lymphoma (DLBCL). Polivy stands as a pioneering anti-CD79b ADC, built upon Seagen’s linker-payload technology: its antibody homes in on the CD79b protein present on B-cells, the conjugated vedotin payload functions as a potent microtubule-disrupting agent, and upon binding, the drug is absorbed into the cancer cell, where the cytotoxic element is released to trigger cell death. Distinctive qualities of this therapy encompass its high selectivity for malignant B-cells, a more manageable safety profile relative to systemic chemotherapy, and a proven 27% decrease in the risk of disease progression or death compared to standard R-CHOP, as demonstrated in the key POLARIX study. This regimen is now positioned to revolutionize first-line DLBCL treatment, likely lowering relapse rates and easing the long-term burden on patients.
Polivy Market Major Participants And Competitive Dynamics
Major companies operating in the polivy market are F. Hoffmann-La Roche Ltd (Genentech Inc.)
Access The Complete Polivy Market Report:
Polivy Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the polivy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polivy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model